Subbotin AS* and Afanasyev NG
PET-CT is currently of significant clinical importance in Hodgkin's lymphoma and is used both for primary staging and tumor re-grading, and for assessing the dynamics of the treatment being performed. In the literature there are indications of the possibility of a lack of accumulation of the radiopharmaceutical in the tumor tissue in Hodgkin's lymphoma before the start of treatment. Low metabolic activity of the tumor tissue prior to treatment makes it difficult to assess the dynamics of the treatment, and when performing resaduring, it can mimic the complete metabolic response in the presence of viable tumor tissue. A study was conducted to determine the frequency of occurrence of low metabolic activity of tumor tissue in Hodgkin's lymphoma. Retrospectively, the results of 131 PET-CT wholebody studies with 18 F - fluorodeoxyglucose were performed on patients with histologically verified Hodgkin lymphoma. The characteristics of the accumulation of 18 F - fluorodeoxyglucose in various histological types of Hodgkin's lymphoma were studied, the dependence of the level of metabolic activity on the presence of general symptoms of intoxication was determined. According to the data obtained, low metabolic activity was determined in 4% of patients with Hodgkin's lymphoma. The highest levels of metabolic activity were determined in case of nodular sclerosis, the lowest - in Hodgkin's nodular lymphoma with lymphoid predominance. Patients with common symptoms were characterized by higher levels of metabolic activity.
English 
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Hindi